Aardvark released exploratory data from its stopped Phase 3 HERO trial in Prader-Willi syndrome after FDA lifted the hold, and plans a redesigned Phase 3.
|Articles|May 23, 2011
The Almac Group Celebrates Grand Opening of New North American Headquarters
Advertisement
The
The $120 million, 240,000-square-foot new North American headquarters houses more than 800 employees and has already brought approximately 300 new hires to the greater Philadelphia region. With global headquarters in Craigavon, Northern Ireland, Almac employs more than 3,000 worldwide, with over 1,100 employees based in the US.
Officially opening the building was former US Senator George J. Mitchell, who was Chairman of the historic 1998 Northern Ireland Peace Agreement. Until last week, Mitchell served as President Obama’s Special Envoy to the Middle East. Commenting on the new facility, Mitchell said, “Almac’s Founder Sir Allen McClay had a real vision for this company, and the building we are dedicating today will be a fitting monument to his life and work. This facility will be important not only to the economy of Pennsylvania, but to the health of people all over the world."
In addition to Senator Mitchell, several other dignitaries participated in the grand opening. These include Pennsylvania Department of Community and Economic Development Secretary C. Alan Walker, who attended on behalf of Pennsylvania Governor Tom Corbett, and Almac CEO Alan Armstron.
Lady Heather McClay, wife of the late
Almac’s new North American headquarters, comprised of a three-story office and administration building, as well as a building for the production, analysis and distribution of clinical trial supplies, was designed by Francis Cauffman Architects of Philadelphia and built by Skanska USA. It strives to maintain sustainability throughout, with low greenhouse gas emissions and a full water reclamation program in place.
Advertisement
Related to this article
Clinical trials capture data faster than ever, but the real bottleneck is the distance between data capture and a decision teams can trust.
In today’s ACT Brief, we examine why the future of AI in trials is a trusted orchestration system rather than a single model, how coordinators rate eSource-enabled workflows, and what a bipartisan bill proposes for reusable trial networks.
The Faster Clinical Trials Act would create an FDA Center for Clinical Trial Innovation and aims to cut trial costs and enrollment time by at least 30%.
Standardized measurement across five oncology centers found that clinical research coordinators rated eSource-enabled workflows positively (Overall Mean Satisfaction 5.79 of 7), with reduced manual entry and electronic data transfer earning strong marks, while perceived reduction in sponsor and monitor queries lagged as the one domain below threshold.
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, describes the industry’s trajectory toward a unified intelligence orchestration environment—and explains why the future isn’t one model that knows everything, but a trusted system that brings the right evidence to the right human decision.
In today’s ACT Brief, we examine how sites can avoid both fear-driven and overly aggressive AI adoption, why community-based research needs sustained financial investment, and why patient access matters more than organizational size.
Pacing obesity trial enrollment, anchoring eligibility to stable real-world therapies, and building site and physician relationships improve retention and data quality more than aggressive recruitment or restrictive exclusion criteria do.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Building Standardized Evidence for eSource-Enabled Clinical Trials: Multi-Site Validation of a Clinical Research Coordinator Satisfaction Methodology
2
Bipartisan Bill Would Build Reusable Clinical Trial Networks, With a Focus on Rare Disease
3
Where the Industry Is Headed as Clinical, Operational, and Real-World Data Connect
4
ACT Brief: Orchestrated AI Clinical Environments, eSource Coordinator Satisfaction, and Faster Clinical Trials Act
5